Core Viewpoint - The company plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which constitutes a major asset restructuring and related party transaction, but will not change the actual controller of the company [3][76]. Group 1: Board Meeting Details - The second meeting of the board of directors was held on October 31, 2025, with all nine directors present, and the meeting complied with relevant laws and regulations [2]. - The board unanimously agreed to waive the advance notice period for the meeting [2]. Group 2: Approval of Asset Purchase - The board approved the proposal for issuing shares to purchase assets and confirmed that the transaction complies with relevant laws and regulations [3][4]. - The proposal was reviewed and approved by the board's strategic committee and independent directors prior to the meeting [4][28]. Group 3: Transaction Details - The company intends to acquire 100% equity of Weigao Purui from Weigao Group, Weihai Shengxi Enterprise Management Consulting Center, and Weihai Ruiming Enterprise Management Consulting Partnership [7]. - The shares to be issued will be domestic listed RMB ordinary shares (A-shares) with a par value of RMB 1.00, listed on the Shanghai Stock Exchange [9]. Group 4: Pricing and Issuance - The pricing benchmark date for the share issuance is the date of the board meeting announcement, with the issuance price set at RMB 31.29 per share, not lower than 80% of the average trading price over the previous 20 trading days [14][15]. - The number of shares to be issued is yet to be determined, pending the final transaction price [17]. Group 5: Lock-up and Performance Commitments - The newly issued shares will have a lock-up period of 36 months, with extensions under certain conditions [20]. - As of the meeting date, no performance compensation agreements have been finalized, and these will be determined in accordance with regulatory requirements [22]. Group 6: Regulatory Compliance - The board confirmed that the transaction meets the requirements of the Major Asset Restructuring Management Measures and other relevant regulations [44]. - The company has taken necessary confidentiality measures regarding the transaction [66]. Group 7: Stock Suspension and Resumption - The company's stock was suspended from trading on October 20, 2025, due to the planned asset acquisition [76]. - The stock is scheduled to resume trading on November 3, 2025, following the board's approval of the transaction proposals [78].
山东威高血液净化制品股份有限公司第二届董事会第十七次会议决议公告